SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Insider Trade Summary
Other: 300,394 shares
Other
17 txns
Insider
Mottola Frank
Role
SVP, Chief Tech. Ops. Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Restricted Stock Unit F2, F3 | 100,000 | $0.00 | $0.00 |
| Other | Performance Share Unit F4, F2, F5 | 3,500 | $0.00 | $0.00 |
| Other | Performance Share Unit F4, F2, F6 | 3,350 | $0.00 | $0.00 |
| Other | Performance Share Unit F4, F2, F7 | 3,750 | $0.00 | $0.00 |
| Other | Restricted Stock Unit F8, F2, F9 | 1,875 | $0.00 | $0.00 |
| Other | Restricted Stock Unit F8, F2, F10 | 2,500 | $0.00 | $0.00 |
| Other | Restricted Stock Unit F8, F2, F11 | 3,375 | $0.00 | $0.00 |
| Other | Restricted Stock Unit F8, F2, F12 | 3,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F2, F13 | 14,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F2, F14 | 22,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F2, F15 | 17,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F2, F16 | 18,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F2, F17 | 30,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F2, F18 | 25,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F2, F19 | 20,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F2, F20 | 13,500 | $0.00 | $0.00 |
| Other | Common Stock F1 | 19,544 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Unit — 0 contracts (Direct);
Performance Share Unit — 0 contracts (Direct);
Employee Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Holdings Before and After:
Restricted Stock Unit, 110,750 to 0 contracts (Direct);
Performance Share Unit, 10,600 to 0 contracts (Direct);
Employee Stock Option (Right to Buy), 159,500 to 0 contracts (Direct);
Common Stock, 19,544 to 0 shares (Direct)
Footnotes (20)
- F1. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
- F2. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F3. These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in five installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.
- F4. Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
- F5. On February 18, 2026, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on July 15, 2026.
- F6. On February 19, 2025, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on May 3, 2025.
- F7. On February 22, 2024, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on June 24, 2024.
- F8. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F9. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
- F10. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
- F11. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
- F12. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.
- F13. Option vests in four equal installments beginning February 22, 2020.
- F14. The option vests in four equal annual installments beginning on February 21, 2021.
- F15. The option vests in four equal annual installments beginning on February 19, 2022
- F16. The option vests in four equal annual installments beginning on February 22, 2023.
- F17. The option vests in four equal annual installments beginning on February 23, 2024.
- F18. The option vests in four equal annual installments beginning on February 22, 2025.
- F19. The option vests in four equal annual installments beginning on February 19, 2026.
- F20. The option vests in four equal annual installments beginning on February 18, 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
